Investor Relations
Financial Calendar
- 02/05/24
2023 Annual Report
- 16/05/24
Interim report, Q1 2024
- 23/05/24
Annual General Meeting, 2024
- 15/08/24
Half-year report, Q2 2024
- 14/11/24
Interim report, Q3 2024
- 06/02/25
Year-end report, Q4 2024
- 01/05/25
2024 Annual Report
Latest press releases
ExpreS2ion to present in investor and R&D events in March
Non-regulatory pressreleaseHørsholm, Denmark, 29 February 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in investor and R&D events during March.
Read moreExpreS2ion’s Associated Company AdaptVac Receives Milestone Payment Following Completion of Bavarian Nordic’s Clinical Phase III Study for the COVID-19 Vaccine
Regulatory pressreleaseHørsholm, Denmark, 21 February 2024 – ExpreS[2]ion Biotech Holding AB’s affiliate ExpreS[2]ion Biotechnologies ApS (“ExpreS2ion") today announces that AdaptVac ApS (“AdaptVac”) has received 10 million EUR as a result of Bavarian Nordic having completed the clinical Phase III study of the COVID-19 vaccine ABNCoV2. The board of AdaptVac, in line with authority granted through AdaptVac’s…
Read more